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STATE-OF-THE-ART PAPERCSTATE-OF-THE-ART PAPER391Rehospitalization for Heart Failure: Problems and PerspectivesMihai Gheorghiade, Muthiah Vaduganathan, Gregg C. Fonarow, Robert O. Bonow
Heart failure (HF) is associated with high morbidity, mortality, and health care expenditures.
Rates of rehospitalization for HF patients continue to rise and approach 30% within 60 to 90
days of discharge. HF readmission is increasingly being used as a quality metric, a basis for
hospital reimbursement, and an outcome measure in HF clinical trials. Gheorghiade and
colleagues discuss management strategies that may help reduce HF rehospitalizations
including adopting a mechanistic approach to cardiac abnormalities, treating noncardiac
comorbidities, increasing utilization of evidence-based therapies, and improving care
transitions, monitoring, and disease management.CLINICAL RESEARCH CLINICAL TRIAL
404olchicine Appears to Be Useful for
Secondary Prevention of Cardiovascular DiseaseStefan M. Nidorf, John W. Eikelboom, Charley A. Budgeon, Peter L. Thompson
Nidorf and colleagues hypothesized that because activated neutrophils are present in unstable
atherosclerotic plaques, inhibition of neutrophil function with colchicine would reduce the risk
of plaque rupture. A total or 532 patients with stable coronary disease were randomly
assigned colchicine 0.5mg/day or no colchicine and followed for a median of 3 years. The
primary outcome, a composite of acute coronary syndrome [ACS], out-of-hospital cardiac
arrest or non cardio-embolic ischemic stroke, occurred in 5.3% of patients assigned colchicine
and 16% assigned no colchicine (hazard ratio: 0.33). Colchicine appears to be effective for the
secondary prevention of cardiovascular events.
Editorial Comment: Robert A. Vogel, James Forrester, page 411(continued on page A-26)
JANUARY 29, 2013 (continued) A-26INTERVENTIONAL CARDIOLOGY4135-Year Outcome After Transcatheter Aortic Valve ImplantationStefan Toggweiler, Karin H. Humphries, May Lee, Ronald K. Binder, Robert R. Moss, Melanie Freeman,
Jian Ye, Anson Cheung, David A. Wood, John G. Webb
Toggweiler and colleagues reviewed the long-term outcomes of patients who underwent
successful transcatheter aortic valve implantation (TAVI) with a balloon-expandable valve.
These first 88 patients had a successful procedure and survived at least 30 days after the
procedure. At 5 years, 3 patients (3.4%) had signs of moderate prosthetic valve dysfunction.
Survival rates at 1 to 5 years were 83%, 74%, 53%, 42%, and 35%, respectively, with a
median survival time of 3.4 years. Patients with chronic obstructive pulmonary disease
(COPD) were at twice the risk of death;  moderate paravalvular regurgitation was
associated with a tripling of the risk of death. This study demonstrates favorable long-term
outcomes after TAVI.INTERVENTIONAL CARDIOLOGY420Increasing Use of Transradial Access for STEMIDmitri V. Baklanov, Lisa A. Kaltenbach, Steven P. Marso, Sumeet Subherwal, Dmitriy N. Feldman,
Kirk Garratt, Jeptha Curtis, John Messenger, Sunil V. Rao
Baklanov and colleagues reviewed data from the CathPCI Registry to determine the use of
and outcomes with radial access for percutaneous coronary intervention (PCI) in patients with
ST-segment elevation myocardial infarction (STEMI). Over the 5-year period, 2007 to 2011,
the use of transradial (TR) access increased from 0.9% to 6.4%. There was no difference in
procedural success between TR and femoral access though transradial was associated with a
slightly longer median door-to-balloon time (78 vs. 74 min). TR access was associated with
lower adjusted risk of bleeding and lower adjusted risk of in-hospital mortality. These data
support the use of TR access for STEMI.CARDIOMETABOLIC RISK427Remnant Cholesterol as a Cardiac Risk FactorAnette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B. Jørgensen, Ruth Frikke-Schmidt,
Børge G. Nordestgaard
Remnant cholesterol is composed of very low-density lipoproteins and intermediate-density
lipoproteins in the fasting state, with the addition of chylomicron remnants in the non-fasting
state. Varbo and colleagues assessed the cardiac risk of non-fasting remnant cholesterol using
the Mendelian randomization approach. Genetic variants associated with a single lipoprotein
were determined in almost 75,000 individuals from Copenhagen, of which more than 1 in 6
had ischemic heart disease. The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic increase
of non-fasting remnant cholesterol was 2.8, with a corresponding observational hazard ratio of
1.4. For LDL cholesterol corresponding values were 1.5 and 1.1. This implies that remnant
cholesterol lipoprotein particles cause ischemic heart disease.
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Lavigne and Karas performed a meta-analysis of randomized controlled trials of niacin.
Eleven eligible trials including 9,959 subjects were identified. The incidence of the primary
composite cardiovascular disease (CVD) endpoint was significantly reduced in niacin-treated
patients (odds ratio: 0.66). The magnitude of on-treatment high-density lipoprotein
cholesterol (HDL-C) difference between treatment arms was not associated with the
magnitude of the effect of niacin on outcomes. These results confirm that niacin reduces
CVD events, but suggest that this may occur through pleiotropic mechanisms rather than
simply raising HDL-C concentration.HEART FAILURE447Autonomic Neuropathy May Contribute to LV Remodeling in DiabeticsRodica Pop-Busui, Patricia A. Cleary, Barbara H. Braffett, Catherine L. Martin, William H. Herman,
Phillip A. Low, Joao A. C. Lima, David A. Bluemke, for the DCCT/EDIC Research Group
Pop-Busui and colleagues sought to determine the association between cardiovascular
autonomic neuropathy (CAN) and left ventricle (LV) structure and function in patients with
type 1 diabetes (T1DM). All subjects had cardiac magnetic resonance imaging (CMRI);
CAN was assessed by cardiovascular reflex testing (R-R response to paced breathing, Valsalva
ratio, and blood pressure response to standing). Systolic function was not different between
subjects with CAN and those without CAN. In multiple-adjusted analyses, participants with
CAN had significantly higher LV mass, mass-to-volume-ratio, and cardiac output. These
results suggest a link between CAN and LV concentric remodeling.HEART RHYTHM DISORDERS IN HEART FAILURE455QOL and Functional Capacity in Patients With AF and CHFIrina Suman-Horduna, Denis Roy, Nancy Frasure-Smith, Mario Talajic, François Lespérance,
Lucie Blondeau, Paul Dorian, Paul Khairy, on behalf of the AF-CHF Trial Investigators
Suman-Horduna and colleagues randomized subjects with atrial fibrillation (AF) and
congestive heart failure (CHF) to rhythm- versus rate-control treatment strategies. For this
pre-specified substudy of the AF-CHF trial, quality of life (QOL) was determined by
questionnaire and 6-min walk tests were conducted. QOL improved to a similar extent with
rhythm- and rate-control; however, a higher proportion of time spent in sinus rhythm was
associated with a modestly greater improvement in QOL scores. A higher proportion of time
spent in sinus rhythm was also associated with a greater improvement in New York Heart
Association functional class but not in 6-min walk distance.
Editorial Comment: Michael H. Kim, page 461.(continued on page A-28)
JANUARY 29, 2013 (continued) A-28F
w
S
dHEART RHYTHM DISORDERS IN HEART FAILURE463Omega-3 Fatty Acids Fail to Prevent Recurrent AFAlejandro Macchia, Hugo Grancelli, Sergio Varini, Daniel Nul, Nicola´s Laffaye, Javier Mariani,
Daniel Ferrante, Raúl Badra, Julio Figal, Silvina Ramos, Gianni Tognoni, Herna´n C. Doval,
on behalf of the GESICA Investigators
The FORWARD trial was a randomized placebo-controlled trial to evaluate the efficacy of
n-3 polyunsaturated fatty acids (PUFA) for the prevention of recurrent atrial fibrillation (AF).
All subjects had previous symptomatic AF and were in normal sinus rhythm. There were no
significant differences in the rates of recurrent symptomatic AF at 12 months. There was no
difference in any of the other pre-specified endpoints including all-cause mortality, nonfatal
stroke, nonfatal acute myocardial infarction, systemic embolism, heart failure, or severe
bleeding. These results suggest that there is no benefit to pharmacological supplementation
with 1 g of n-3 PUFA for patients with previous AF.CARDIAC IMAGING
469lurpiridaz F-18 PET Myocardial Perfusion
Imaging for Detection of Coronary Artery DiseaseDaniel S. Berman, Jamshid Maddahi, B.K. Tamarappoo, Johannes Czernin, Raymond Taillefer,
James E. Udelson, C. Michael Gibson, Marybeth Devine, Joel Lazewatsky, Gajanan Bhat, Dana Washburn
Flurpiridaz, labeled with positron emitting isotope fluorine-18 (F-18), is a novel
radiopharmaceutical for use with positron emission tomography (PET). Berman and
colleagues report the results of a phase II trial assessing the clinical safety of flurpiridaz F-18
and comparing its diagnostic performance to Tc-99m single-photon emission computed
tomography (SPECT)-myocardial perfusion imaging (MPI). Subjects underwent both rest-
stress PET and Tc-99m SPECT-MPI and most had contemporaneous invasive coronary
angiography (ICA). Almost 100% of the stress PET images were rated as excellent/good
compared to 88% of the SPECT images. Diagnostic certainty of interpretation was higher for
PET versus SPECT (91% vs. 71%) and the sensitivity for detecting a 50% stenosis on ICA
as higher. In this Phase 2 trial, PET MPI using flurpiridaz F-18 was safe and superior to
PECT MPI for image quality, interpretative certainty, and overall coronary artery disease
iagnosis.
